African children under 5 years of age bear the main burden of global malaria mortality. Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ) given monthly during the rainy season is a highly effective malaria intervention for children aged between 3 months and 5 years living in the Sahel region, a region of intense but seasonal malaria transmission. This intervention is now being considered for other regions of Africa where malaria parasites are more drug resistant. Dihydroartemisinin-piperaquine (DP), an artemisinin-based combination therapy (ACT), has proved to be highly effective and well tolerated in intermittent preventive treatment in pregnant women and children. This combination may be a suitable alternative for SMC. Understanding the safety, pharmacokinetic and pharmacodynamic properties of antimalarial combination therapies is crucial in optimising dosing.
Ivan Alejandro Pulido Tarquino, Chayanin Sararat, Kanokon Suwannasin, Stéphane Proux, Urairat Koesukwiwat, Joel Tärning, Katherine Theiss-Nyland, F. Nosten, Sir Nicholas White
Palang Chotsiri, Issaka Zongo, Paul Milligan, Yves Daniel Compaoré, Anyirékun Fabrice Somé, Daniel Chandramohan, Warunee Hanpithakpong, François Nosten, Brian Greenwood, Philip J. Rosenthal, Sir Nicholas White, Jean‐Bosco Ouédraogo, Joel Tärning
Craig Bonnington, Anthony Nuwa, Katherine Theiss-Nyland, Richard Kajubi, Moses R. Kamya, Joaniter I. Nankabirwa, Chris Ebong, Jane Nabakooza, Jimmy Opigo, David Salandini, O.I Musa, Chayanin Sararat, James A Watson, Kanokon Suwannasin, Stéphane Proux, Urairat Koesukwiwat, Joel Tärning, Mallika Imwong, James Tibenderana, François Nosten, Sir Nicholas White
Discussion(0)
No comments yet. Be the first to comment.